Compounds for the treatment of inflammation of the central...

Details Compounds for the treatment of inflammation of the central... Compounds for the treatment of inflammation of the central...

A - Human Necessities

61

K

A61K 31/549 (2006.01) A61P 25/00 (2006.01)

Patent

CA 2571717

The invention relates to KATP channel openers (KCOs) which can be used for the prophylactic and/or therapeutic treatment of chronic inflammation of the central nervous system (CNS) which is associated with a disease or condition in mammals, including humans. The administration of KCOs, including groups comprising benzopyranes, cyanoguanidines, thioformamides, benzothiadizine, pyridyl nitrates, pyrimidine sulphates, cyclobutenediones, DHP-related compounds, tertiary carbinols, 6-sulfonyl-cromenes, 1,2,3 triazoles, pyridothiadiazines, benzothiazines, halogenoquinazolines and phenylbenzimidazoles and, in particular, diazoxide compound, produce a reduction in the reactive microglial response in various CNS pathologies, such as axonal lesions, cerebral tumours, traumatic injuries, neurodegeneration, spinal cord lesions and autoimmune and infectious diseases. In addition, isotopically-modified KCOs can also be used for the preparation of diagnostic agents for the detection and monitoring of chronic inflammation of the CNS.

Les activateurs du canal de K<SB>ATP</SB> (KCO) sont utiles dans le traitement prophylactique et/ou thérapeutique de l'inflammation chronique du système nerveux central associée à une maladie ou à un état chez un mammifère, entre autres un être humain. L'administration de KCO, y compris les groupes de benzopiranes, cyanoguanidines, thioformamides, benzotiadizines, pyrridyle nitrates, pyrimidine sulfates, cyclobutènediones, composés en rapport avec le DHP, carbynoles tertiaires, 6-sulfonil-cromènes, 1,2,3 triazoles, pyridotiadiazines, benzotiazines, halogénoquinazolines et phénylbenzymidazoles, et plus particulièrement, le composé diazoxydo, produisent une réduction de la réponse de la microglie réactive dans diverses pathologie du système nerveux central telles que la lésion axonale, des tumeurs cérébrales, un trouble traumatique, une neurodégénérescence, une lésion de la médule spinale et des maladies autoimmunes et infectieuses. Les KCO, modifiés isotopiquement, sont également utiles dans la préparation d'agents de diagnostic pour la détection et le suivi de l'inflammation chronique du système nerveux central.

Affiliated with

Also associated with

Rating

Compounds for the treatment of inflammation of the central... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of inflammation of the central..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of inflammation of the central... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2001705